Results 151 to 160 of about 1,419,720 (263)

Hip Fracture Risk of Lemborexant and Suvorexant in Comparison With Z‐Drugs: A Target Trial Emulation

Journal of the American Geriatrics Society, EarlyView.
ABSTRACT Background Lemborexant and suvorexant are widely used dual orexin receptor antagonists (DORAs) for the pharmacological treatment of insomnia. Although they are generally considered safer than benzodiazepine receptor agonists (Z‐drugs) regarding adverse events including hip fractures, evidence from direct comparisons remains limited. This study
Yuichiro Matsuo, Hayato Yamana, Yusuke Sasabuchi, Hiroki Matsui, Takahide Kohro, Hideo Yasunaga   +5 more
wiley   +1 more source

Inpatient Cardiac Resynchronization Therapy During Heart Failure Hospitalization: A Distinct High‐Risk Phenotype

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Background The role of cardiac resynchronization therapy (CRT) during hospitalization for heart failure (HFH) is uncertain, because hospitalized patients were routinely excluded from landmark CRT trials. Despite this, CRT implantation during HFH is common.
Oliver Rees, James Dargan, Jemima Weir, Robin Ray, Giuseppe Rosano, Fadi Johura   +5 more
wiley   +1 more source

Practical Implementation of Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists in the Management of Heart Failure. [PDF]

JACC Adv
Michos ED, Ambrosy AP, Fonarow GC.
europepmc   +1 more source

Advanced Conduction Disease After Incident Heart Failure in Myotonic Dystrophy Type 1

Pacing and Clinical Electrophysiology, EarlyView.
Central Figure. Advanced Conduction Disease After Incident HF in Myotonic Dystrophy Type 1. ABSTRACT Background Myotonic dystrophy type 1 (DM1) is associated with progressive cardiac conduction disease, heart failure (HF) and increased mortality. However, the association of incident HF with conduction disease and survival in DM1 is not well defined ...
Isadora Guarino, Lauren Elman, Gregory Supple, Saman Nazarian   +3 more
wiley   +1 more source

Mineralocorticoid Receptor Antagonists for Liver Fibrosis: Potential Mechanisms and Research Progress. [PDF]

J Clin Transl Hepatol
Zheng H, Feng Y.
europepmc   +1 more source

Leptin–cholesterol crosstalk in pregnancy: Mechanistic implications for placental function and cardiometabolic programming

Experimental Physiology, EarlyView.
Abstract Pregnancy requires the coordinated maternal reorganization of lipid and endocrine pathways to sustain fetal growth and anticipate neonatal nutrition. Leptin, produced by adipose tissue and the placenta, acts as an integrative signal linking maternal energy status with trophoblast function and vascular adaptation, while cholesterol provides ...
Julio Flores, Diego Gumera, Andreina Arias, Cristián A. Amador, María José Yañez   +4 more
wiley   +1 more source

Glucocorticoids modulate drug transporter function in human fetal brain endothelial cells

The Journal of Physiology, EarlyView.
Abstract figure legend P‐glycoprotein and breast cancer resistance protein are the most prominent drug transporters at the fetal blood–brain barrier. We isolated primary human fetal brain endothelial cells from early and mid‐gestation cerebral microvessels and exposed them to glucocorticoids cortisol and dexamethasone in vitro.
Nikola Ivanovski, Phetcharawan Lye, Enrrico Bloise, Stephen G. Matthews   +3 more
wiley   +1 more source

The impact of mineralocorticoid receptor antagonists on fat mass and fat metabolism. [PDF]

J Endocrinol Invest
Afsar B, Afsar RE, Maddukuri G.
europepmc   +1 more source

A Novel NR3C1 Frameshift Variant Associated With Familial Glucocorticoid Resistance Syndrome: An Integrated Analysis of Steroid Profiling and Structural Modeling

American Journal of Medical Genetics Part A, Volume 200, Issue 12, Page 2719-2737, December 2026.
ABSTRACT Glucocorticoid resistance syndrome (GRS) is a rare hereditary disorder caused by pathogenic variants in NR3C1, characterized by marked phenotypic heterogeneity and frequent misdiagnosis as primary aldosteronism or subclinical Cushing's syndrome.
Sufang Yun, Zhifeng Zhu, Fengye Zhou, Ying Liu, Chunfang Liang, Haitao Ju, Lin Lu, Zhaoli Yan   +7 more
wiley   +1 more source

Pharmacovigilance profiles of three generations of mineralocorticoid receptor antagonists and network toxicology analysis. [PDF]

Front Med (Lausanne)
Lin HH, Cui WH, Xu F, He JY, Li LC, Xu JJ, Jiang X, Mao KL.   +7 more
europepmc   +1 more source